Cantor Fitzgerald Rates Gilead Sciences (GILD) buy

Cantor Fitzgerald maintains a buy rating for Gilead Sciences with a target price of $155, a 24.13% upside from the current price.

By TradeTexts Research Desk · Published Jun 16, 2026, 10:02 AM EDT · Updated Jun 23, 2026, 7:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Cantor Fitzgerald rated Gilead Sciences, Inc. ($GILD) "buy" with a $155 price target on June 16, 2026.

Since the rating, $GILD is down 1.7% after 1 week, up 7.1% after 1 month and up 23.4% to date (from the $126.52 close on Jun 16, 2026).

GILD Gilead Sciences, Inc.

$156.19 +30.76% year to date

Daily close · Oct 16, 2026

Key Points

Cantor Fitzgerald reiterated its buy rating for Gilead Sciences, Inc. (GILD) on June 16, 2026, with a target price of $155.
Cantor Fitzgerald's $155 price target implies 24.13% upside from Gilead Sciences, Inc.'s ($GILD) current $124.87 share price.
Shares of NasdaqGS:GILD traded near $124.3, with a market cap of $154.3 billion and a forward P/E of 12.86.
Insiders at Gilead Sciences were active, with notable transactions by key executives on June 10, 2026.

Get $GILD trade alerts by text

We text you when insiders, Congress or big funds trade $GILD. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Gilead Sciences, Inc. alert may contain errors. Disclosures

Cantor Fitzgerald reiterated its buy rating on Gilead Sciences, Inc. (NasdaqGS: GILD) on June 16, 2026. The firm set a price target of $155 for the biopharmaceutical company, which specializes in developing and commercializing medicines to address unmet medical needs.

Gilead Sciences, Inc. Stock Down 20.7%

Shares of Gilead Sciences traded near $124.3 on the NasdaqGS. The company boasts a market cap of approximately $154.3 billion. Its forward P/E ratio stands at 12.86, suggesting a relatively favorable valuation compared to its past earnings. The stock has a 52-week range between $104.46 and $157.29, with a 50-day moving average of $132.66 and a 200-day moving average of $129.21. Gilead exhibits a beta of 0.331, indicating lower volatility compared to the broader market.

12-month forecast

$GILD price target

Gilead Sciences, Inc. daily closes and this analyst's $155 target. Not advice.

Recent Earnings

In its most recent financial results, Gilead Sciences reported revenue of $29.7 billion, reflecting a growth of 4.4%. The company achieved an earnings per share (EPS) of $7.35 and maintained a net margin of 30.99%. The return on equity (ROE) was an impressive 43.36%. Investors can expect the next earnings report on August 6, 2026.

Dividend

Gilead Sciences offers an annual dividend rate of $3.28, yielding 2.64% at current prices. The dividend payout ratio is 43.4%, indicating a conservative approach to returning capital to shareholders.

Insider Buying and Selling at Gilead Sciences, Inc.

On June 10, 2026, several insiders at Gilead Sciences engaged in stock transactions. Chief Medical Officer Dietmar Berger sold 263 shares at an average price of $121.48. Chairman and CEO Daniel Patrick O'Day also sold shares, with 8,779 shares offloaded. On the buying side, CFO Andrew Dickinson purchased 2,796 shares, while Dietmar Berger bought 533 shares, reflecting mixed insider activity.

Analysts Set New Price Targets

On June 16, 2026, Cantor Fitzgerald reiterated its buy rating for Gilead Sciences with a target price of $155. This follows similar positive sentiment from Maxim Group, which upgraded the stock to a buy with a $165 target on May 20, 2026. Truist Securities also reiterated a buy rating with a $157 target on May 8, 2026. The consensus among analysts remains a buy, with a mean target price of $157.57 based on 28 opinions.

About Gilead Sciences

Gilead Sciences, Inc. is a leading biopharmaceutical company headquartered in Foster City, California. It focuses on discovering, developing, and commercializing medicines for various unmet medical needs worldwide. The company is known for its treatments for HIV, hepatitis, and other serious illnesses. With a workforce of around 17,000 employees, Gilead continues to innovate and expand its product offerings under the leadership of CEO Daniel Patrick O'Day.

Bottom Line

Cantor Fitzgerald's reaffirmation of a buy rating on Gilead Sciences underscores confidence in the company's future prospects. Investors track such analyst ratings closely as they can influence market sentiment. It's important to note that these ratings reflect backward-looking assessments and are part of a broader analysis of the stock's potential.